SELLAS Life Sciences Group, Inc. (SLS) Technical Analysis & Indicators
SELLAS Life Sciences Group, Inc. (SLS) — Price $10.38 (closing price, October 28, 2026) — Healthcare — Biotechnology — NASDAQ
Latest reported results:
Technical analysis of SELLAS Life Sciences Group, Inc. (SLS): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc.